Location: Cheshire, UK
Salary: Competitive + excellent benefits (£k - £k for search optimisation only)
The next generation of medicines.
How will you take them even further?
At AstraZeneca, we’re constantly striving to make new discoveries. Discoveries that will make a meaningful difference to health globally. We already have an exceptional product pipeline, and everyone here has a part to play in making sure that pipeline fulfils its potential. This is your opportunity to join them – and to fulfil your own.
We have an exciting opportunity for you to work with ubiquitin ligases, which constitute a large class of enzymes that play a pivotal role in cellular homeostasis by modulating protein stability and signalling in a plethora of cellular pathways that are critical determinants of health and disease. Ubiquitination of target proteins requires the sequential action of three enzymes – E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme) and E3 (ubiquitin ligase enzyme) – culminating in the covalent attachment of a ubiquitin moiety to target proteins. Our objective is to understand the biology of select ubiquitin ligases using cutting-edge technologies. This project will be carried out in close collaboration with the University of Dundee.
You’ll prioritise their research activities around establishing and validating our In Situ Ubiquitin Ligase Profiling system and propose novel and innovative cellular and biochemical technologies and techniques aimed at interrogation of the ubiquitin ligase of choice within the cell. You’ll also identify tool compounds against ubiquitin ligase under study and deliver detailed in vitro target validation through application of quantitative mass spectrometry, molecular and cellular biology techniques, and protein biochemistry. You’ll build a cross-functional research project at the frontiers of ubiquitin biology and we’ll encourage you to present your results internally and through publication.
Your major responsibilities
• Establish a generic cellular ubiquitin ligase assay guided by our In Situ Ubiquitin Ligase System
• Identify a chemical toolkit against ubiquitin ligase of choice through application of high throughput screening
• Carry out detailed in vitro target validation and use identified tool compounds to define the landscape of ubiquitin ligase substrates
• Apply molecular and cellular biology combined with protein biochemistry techniques to analyse the functional implications of substrate ubiquitination, deduce new hypotheses and drive project science
A PhD in one of the following areas:
• Molecular cell biology
• Protein biochemistry
• Cell biology
• A PhD in molecular cell biology covering molecular signalling of ubiquitin and ubiquitin ligases, cancer biology or DNA damage and repair
• Experience in one of these technologies is required: protein biochemistry, two-hybrid technology, protein mass spectrometry and protein post-translational analysis or quantitative SILAC as well as strong background in mammalian cell biology, molecular biology, cellular imaging and related technologies
AstraZeneca – Health Connects Us All
As one of the world's leading pharmaceutical companies, our business is focused on providing innovative, effective medicines that make a real difference in important areas of healthcare. What’s more, we support and encourage our people in discovering their own potential. Excellent learning and development opportunities will be available to you throughout your career here.
AstraZeneca welcomes applications from all sections of the community.
AstraZeneca Pharmaceuticals LP
Deadline: April 29th 2013